Docetaxel
| Evidence Level: L2 | Predicted Indications: 7 |
Table of Contents
Docetaxel: Microtubule-stabilizing taxane → Ewing sarcoma
One-Sentence Summary
Docetaxel is a taxane chemotherapy drug that stabilizes microtubules and blocks cancer cell division. The TxGNN model predicts it may be effective for Ewing sarcoma, with 8 clinical trials and 20 publications retrieved for this direction. Most of this evidence comes from combination regimens (such as gemcitabine plus docetaxel) in mixed sarcoma populations, so the contribution of docetaxel alone is hard to isolate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Ewing sarcoma |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L2 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for docetaxel is not available in the data compiled for this report. Based on its known drug class, docetaxel is a taxane that stabilizes microtubules and interferes with cell division. This kind of antimitotic action is plausible in rapidly proliferating sarcoma cells.
Laboratory and clinical work support a particular sequence: gemcitabine followed by docetaxel showed synergistic cytotoxicity in sarcoma cell cultures and in patients. Single-agent docetaxel appears to have limited activity. A small phase II study of docetaxel alone in relapsed or refractory Ewing’s tumours (14 patients) and a Children’s Oncology Group study in recurrent pediatric solid tumours both point to modest activity.
An important caveat is that the studies mostly involve combination regimens in mixed populations of pediatric and young adult sarcoma patients. The benefit attributable to docetaxel alone for Ewing sarcoma is therefore uncertain.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00073983 | Phase 2 | Completed | 54 | Sequential gemcitabine then docetaxel in recurrent Ewing sarcoma, osteosarcoma and chondrosarcoma (mixed population) |
| NCT03449901 | Phase 2 | Completed | 98 | ADI-PEG 20 with gemcitabine and docetaxel in sarcomas, including Ewing sarcoma; docetaxel is part of the backbone |
| NCT00002825 | Phase 2 | Completed | 20 | Single-agent docetaxel in children with recurrent solid tumours; mixed tumour types, modest activity |
| NCT00014456 | Phase 1 | Completed | 35 | Dose escalation of docetaxel, gemcitabine and filgrastim in advanced solid tumours; supports feasibility |
| NCT02511132 | Phase 2 | Completed | 22 | Vigil immunotherapy vs gemcitabine/docetaxel in metastatic Ewing’s sarcoma |
| NCT00049296 | Phase 1 | Completed | 26 | Thalidomide plus docetaxel pharmacokinetics in advanced cancer; not specific to Ewing sarcoma |
| NCT05116800 | Phase 2 | Withdrawn | 0 | 9-ING-41 with gemcitabine/docetaxel in sarcomas; no data |
| NCT04183062 | Phase 2 | Withdrawn | 0 | BIO-11006 added to gemcitabine/docetaxel in osteosarcoma and Ewing sarcoma lung metastases; no data |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22363068 | 2012 | Phase 2 trial | The Oncologist | Sequential gemcitabine and docetaxel in recurrent Ewing sarcoma, osteosarcoma and chondrosarcoma (SARC003) |
| 28787430 | 2017 | Phase 2 trial | Br J Cancer | GEIS-21: intensive chemotherapy including gemcitabine and docetaxel in newly diagnosed high-risk Ewing sarcoma |
| 25164234 | 2014 | Phase 1/2 trial | BMC Cancer | Docetaxel plus irinotecan in recurrent or refractory Ewing sarcoma family tumours |
| 18521364 | 2003 | Phase 2 trial | Sarcoma | Docetaxel alone in 14 patients with relapsed or refractory Ewing’s tumours |
| 18484657 | 2008 | Cohort | Cancer | Gemcitabine plus docetaxel in children and young adults with refractory bone sarcoma |
| 22302783 | 2012 | Retrospective cohort | Pediatr Blood Cancer | GEMDOX in relapsed and refractory pediatric sarcomas |
| 19727011 | 2009 | Cohort | J Pediatr Hematol Oncol | Gemcitabine-docetaxel in relapsed or refractory pediatric sarcomas |
| 15117993 | 2004 | Preclinical/Clinical | J Clin Oncol | Synergy of gemcitabine followed by docetaxel in sarcoma cultures and patients |
| 20132000 | 2010 | Review | Expert Rev Anticancer Ther | Role of chemotherapy in soft tissue sarcomas |
| 26154614 | 2015 | Preclinical | Pediatr Blood Cancer | Pediatric Preclinical Testing Program comparison of cabazitaxel and docetaxel |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 44244 | Chemodoc 80mg Injection | Vial of 2 ml injection | – |
| 251423 | Zenotere 20mg Injection | Vial of 1 ml injection | – |
| 22823 | Axidoxel 120 Injection | Vial of 3 ml injection | – |
| 63494 | Docetere 80mg Injection | Vial of 2 ml injection | – |
| 64150 | Docet 20mg Injection | Vial of 1 injection | – |
At least 20 valid single-ingredient licences are recorded, and the list may be partial.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (taxane class) |
| Myelosuppression Risk | High (neutropenia, thrombocytopenia and anemia are recorded as concerns) |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | Complete blood count with differential, liver function (including bilirubin), signs of peripheral neuropathy, fluid retention |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Conditions of concern (contraindication-related relations recorded for this drug): liver disease, gallbladder disease, thrombocytopenia, neutropenia, agranulocytosis, peripheral neuropathy and other nervous system disorders, anemia, hyperbilirubinemia (including Gilbert syndrome), diarrheal disease, pulmonary edema, stomatitis, neuritis, cardiac tamponade. These are not taken from label text and should be checked against the package insert.
- Drug Interactions: 569 interactions were recorded. Notable examples:
- Major: clarithromycin
- Moderate: aprepitant, rolapitant, metronidazole, tinidazole, cimetidine, miconazole, eliglustat, rosuvastatin, simvastatin, troglitazone
- Minor: dexamethasone, prednisolone, prednisone, levofloxacin
Please also refer to the package insert for warnings, as label warnings and contraindications are not recorded in the local data.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several completed phase 2 trials and phase 1/2 publications address Ewing sarcoma directly, but they are mostly combination regimens in mixed populations, and single-agent docetaxel activity appears limited. The contribution of docetaxel itself is unproven, so this is best treated as a research question rather than a ready-to-adopt use.
To proceed, the following is needed:
- Studies that isolate docetaxel’s contribution, ideally comparing regimens with and without it in Ewing sarcoma
- Package insert warnings and contraindications from the Indian licences
- Detailed mechanism-of-action data
- A monitoring plan for myelosuppression and neuropathy, especially in children and young adults
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.